
Browsing restrictions can be lifted for a fee.
-1.64%
Biote corp.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Biote corp. (BTMD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BTMD's short-term business performance and financial health. For the latest updates on BTMD's earnings releases, visit this page regularly.
According to historical valuation range analysis, Biote corp. (BTMD)'s current price-to-earnings (P/E) ratio is 4.3, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, Biote corp. (BTMD) reported an Operating Profit of 8.27M with an Operating Margin of 17.24% this period, representing a decline of 32.15% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Biote corp. (BTMD) announced revenue of 47.96M, with a Year-Over-Year growth rate of -6.67%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Biote corp. (BTMD) had total debt of 106.41M, with a debt ratio of 0.96. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Biote corp. (BTMD) held Total Cash and Cash Equivalents of 28.05M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Biote corp. (BTMD) achieved the “three margins increasing” benchmark, with a gross margin of 71.8%%, operating margin of 17.24%%, and net margin of 17.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BTMD's profit trajectory and future growth potential.
According to the past four quarterly reports, Biote corp. (BTMD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.26. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Biote corp. (BTMD)'s Free Cash Flow (FCF) for the period is 13.38M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1.47% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Biote corp. (BTMD) has a Price-To-Earnings (PE) ratio of 4.3 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.